• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ProNAi Therapeutics adds five to senior management team

ProNAi Therapeutics adds five to senior management team

October 23, 2014
CenterWatch Staff

ProNAi Therapeutics, a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform, has added five seasoned executives to its senior management team.

• Dr. Angie You, chief business and strategy officer, head of commercial
• Wendy Chapman, senior vice president, clinical operations
• Chandra Lovejoy, senior vice president, global regulatory affairs and quality
• Emma McCann, vice president, program management
• James Smith, vice president, corporate affairs

You heads the newly created position of chief business and strategy officer and head of commercial, and will lead the company's strategic and transactional business and commercial efforts. Previously, You was the chief business officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, HR and business development. She led the business development process resulting in the acquisition of Aragon Pharmaceuticals by Johnson & Johnson. She was chief business officer at companies including Synosia Therapeutics and Ren Pharmaceuticals. She also worked at Venrock Ventures and ran the BD process for Anacor Pharmaceuticals, a Venrock portfolio company, resulting in an early phase IIa licensing agreement with Schering.

Chapman heads the newly created position of senior vice president, clinical operations, with corporate accountability for the overall operational deployment of clinical studies. Prior to joining ProNAi, Chapman was the portfolio director at Parexel International. Previously, Chapman was the vice president of clinical operations at YM Biosciences, where she was responsible for the development and management of clinical operations which included project management, clinical monitoring, clinical supply management and data management of phase I-III clinical trials in myelofibrosis and various solid tumor indications. Chapman has more than 25 years of experience in clinical drug development at several pharmaceutical and CROs in Canada and the U.S., including Viventia Biotech, AAI Pharma, Bayer, AstraZeneca and MDS.

Lovejoy heads the newly created position of senior vice president, global regulatory affairs and head of quality, with more than 15 years of progressive experience in global regulatory affairs and drug development in large and small companies overseeing preclinical through post-marketing phases. Most recently, Lovejoy was the vice president of global regulatory affairs at Endocyte, and prior to that she held a leadership role in regulatory affairs at Genentech, primarily on the Avastin program. Lovejoy brings experience driving cutting-edge global regulatory strategy and leading cross-functional team activities including new IND submissions, implementation and conduct of global clinical trials, successful negotiations with both FDA and European health authorities regarding complex pivotal trials, and the submission and review of marketing applications.

McCann heads the newly created position of vice president, program management and joins ProNAi with more than 14 years of progressive experience in clinical research and program management. McCann formerly was senior director, program management at YM BioSciences, where she focused on the progression of the company's lead drug through a myelofibrosis clinical development program.

Smith heads the newly created position of vice president, corporate affairs, primarily responsible for the company's strategic investor relations and corporate communications activities. Smith was formerly vice president, corporate development at SQI Diagnostics, a public multiplex protein assay company serving global pharmaceutical companies. Previously, he was vice president, corporate affairs at YM BioSciences, a public drug development company acquired by Gilead Sciences. He also led the Healthcare practice at TMX Equicom.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing